I guess I need help doing my DD in respect of the

I guess I need help doing my DD in respect of the latest LL results in mTNBC. This is the third day I'm trying in vain to understand the info from the last CC on the slide at 3:50

https://www.youtube.com/watch?v=p3Cn0xWF_lg

According to the first para, the data below is based on the 12mos analysis of 30 mTNBC patients. The second para states that in comparison with SOC the "overall" results for this 30 patients showed only "slightly increased mPFS" with MOS "similar" to SOC (carboplatin only?)

OK. So far nothing to be excited to say the least.

Yet from the third para we learn that 73% of patients from this group of 30 had "significantly better PFS and OS." 73% of 30 is roughly 22 patients. So if almost three fourth of the group had it "significantly better" how come the "overall" results were similar to SOC?

The fourth para makes it even more puzzling by giving stunning numerical values as to how "significantly better" because if PFS for 73% was 400-660% better and MOS 570-990% better then what must have happened to those 27% of patients to have the overall" result no better than SOC? What is the math of this?

Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.